Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Roche Acquires 89bio in $3.5 Billion Deal, Entering MASH Drug Race

Roche Acquires 89bio in $3.5 Billion Deal, Entering MASH Drug Race

Roche has secured a deal to acquire 89bio for up to $3.5 billion, marking a significant entry into the metabolic dysfunction-associated steatohepatitis (MASH) therapeutic space. The acquisition, which follows months of negotiations and interest from multiple pharmaceutical companies, centers around 89bio's promising FGF21 analog, pegozafermin, currently in late-stage development for MASH treatment.

NoahAI News10/2/2025
Ansa Biotechnologies Secures $54.4M in Series B Funding to Revolutionize DNA Synthesis

Ansa Biotechnologies Secures $54.4M in Series B Funding to Revolutionize DNA Synthesis

Ansa Biotechnologies, a San Francisco-based biotech company, has successfully closed an oversubscribed series B financing round, raising a total of $54.4 million. This significant investment will be utilized to expand the company's DNA synthesis production capacity in the United States, potentially transforming the landscape of biopharmaceutical research and development.

NoahAI News10/2/2025
Cartography Biosciences Secures $67M Funding for Novel Cancer Drug Development

Cartography Biosciences Secures $67M Funding for Novel Cancer Drug Development

Cartography Biosciences, a San Francisco Bay Area biotechnology company, has announced a successful $67 million Series B funding round to advance its innovative cancer treatment pipeline. The funding will primarily support the development of CBI-1214, a promising T cell engager targeting colorectal cancer, with clinical trials set to commence in early 2026.

NoahAI News10/2/2025
Bolt Biotherapeutics Halves Workforce Again Amid Clinical Trial Delays

Bolt Biotherapeutics Halves Workforce Again Amid Clinical Trial Delays

Bolt Biotherapeutics, a clinical-stage oncology company, has announced a significant workforce reduction and a delay in its lead immunotherapy program. This move comes as the biotech faces financial pressures and seeks to extend its cash runway.Bolt has made the decision to halve its workforce for the second time in two years. This latest round of layoffs is aimed at preserving capital and extending the company's financial resources into 2027. The drastic measure follows a similar workforce reduction in August 2024, which left the company with 52 employees at the end of that year.

NoahAI News10/2/2025
Takeda Abandons Cell Therapy Research in Strategic Shift

Takeda Abandons Cell Therapy Research in Strategic Shift

In a significant reversal of its previous strategy, Japanese pharmaceutical giant Takeda has announced its decision to exit the field of cell therapy research. This move marks a substantial shift in the company's focus and resource allocation, with implications for both Takeda's future direction and the broader cell therapy landscape.

NoahAI News10/2/2025
FDA Rejects Fortress and Sentynl's Treatment for Rare Pediatric Disease

FDA Rejects Fortress and Sentynl's Treatment for Rare Pediatric Disease

The U.S. Food and Drug Administration (FDA) has issued a complete response letter rejecting the investigational treatment CUTX-101 for Menkes disease, a rare genetic disorder, developed by Fortress Biotech and Sentynl Therapeutics. The decision, announced on Wednesday, cited manufacturing facility issues as the primary reason for the rejection.

NoahAI News10/2/2025
AnaptysBio Announces Strategic Split into Biopharma and Royalty Management Companies

AnaptysBio Announces Strategic Split into Biopharma and Royalty Management Companies

AnaptysBio, a San Diego-based biotechnology company, has unveiled plans to separate its business into two distinct publicly traded entities by the end of 2026. This strategic move aims to sharpen investor focus on the company's diverse asset portfolio and enhance potential value realization.

NoahAI News10/2/2025
Pharmaceutical Industry Hit by Wave of Layoffs Amid Shifting Priorities and Market Challenges

Pharmaceutical Industry Hit by Wave of Layoffs Amid Shifting Priorities and Market Challenges

The pharmaceutical and biotech sectors are experiencing a significant surge in workforce reductions as companies across the industry grapple with financial pressures, pipeline reprioritizations, and strategic realignments. This trend has affected organizations of all sizes, from industry giants to smaller biotechs, resulting in thousands of job cuts in recent months.

NoahAI News10/2/2025
Novartis Secures FDA Approval for Oral BTK Inhibitor Rhapsido in Chronic Hives Treatment

Novartis Secures FDA Approval for Oral BTK Inhibitor Rhapsido in Chronic Hives Treatment

The U.S. Food and Drug Administration (FDA) has approved Novartis' remibrutinib, to be marketed as Rhapsido, for the treatment of chronic spontaneous urticaria (CSU) in adult patients who remain symptomatic despite H1 antihistamine treatment. This approval marks a significant milestone as Rhapsido becomes the first oral and targeted Bruton's tyrosine kinase (BTK) inhibitor for CSU, offering a new treatment option for the estimated 1.7 million Americans affected by this condition.

NoahAI News10/2/2025
Novo Nordisk Terminates $598M Heart Failure Cell Therapy Collaboration with Heartseed Amid Strategic Restructuring

Novo Nordisk Terminates $598M Heart Failure Cell Therapy Collaboration with Heartseed Amid Strategic Restructuring

Novo Nordisk has announced the termination of its $598 million collaboration with Japanese biotech Heartseed, marking a significant shift in the pharmaceutical giant's strategic focus. The decision comes as part of a broader restructuring initiative led by Novo's new CEO, Maziar Mike Doustdar, aimed at concentrating efforts on the company's core business areas of diabetes and obesity.

NoahAI News10/2/2025
New Biotech Aerska Launches with $21M to Develop Brain-Targeted RNA Therapies

New Biotech Aerska Launches with $21M to Develop Brain-Targeted RNA Therapies

Dublin-based biotechnology company Aerska has emerged onto the pharmaceutical scene with a $21 million seed funding round, aiming to revolutionize the delivery of genetic medicines to the brain. The startup, which also maintains research operations in London, is developing innovative "brain shuttle" technology to transport RNA interference (RNAi) drugs across the blood-brain barrier, potentially opening new avenues for treating neurological disorders.

NoahAI News10/2/2025
General Catalyst's HATCo Completes Landmark $515M Acquisition of Summa Health, Marking New Era in Healthcare Investment

General Catalyst's HATCo Completes Landmark $515M Acquisition of Summa Health, Marking New Era in Healthcare Investment

General Catalyst's Health Assurance Transformation Company (HATCo) has finalized its acquisition of Summa Health, an Ohio-based integrated health system, in a groundbreaking $515 million deal. This transaction, which closed on October 1, 2025, marks the first instance of a venture capital firm owning a hospital system and signals a significant shift in healthcare investment strategies.

NoahAI News10/2/2025
«1...555657...67»